Home 2016-10-24T12:33:21+00:00

RadioMedix Selected for National Cancer Institute’s Investor Initiatives and Presentation at BIO Investor Forum

ITG productsSlide thumbnail

Extended partnership between Radiomedix INC and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America

Extended partnership between Radiomedix Inc and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America
logos1Slide thumbnail

RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors

RadioMedix, Inc., received an exclusive distributions rights for SEDECAL Preclinical PET-CT and PET-MR systems in North America.
Slide thumbnail
The Phase II Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance
RadioMedix and AREVA Med - SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.
Slide thumbnail
RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)
Slide thumbnail
RadioMedix Successful Installations of SmartMedixTM  and AIO fully automated synthesizer modules in USA.
NIH NCI SBIR Contract Award for targeted alpha-TAT of metastatic melanoma. The third collaborative grant for RadioMedix and Viewpoint.
RadioMedix secured a second SBIR NCI grant for image guided therapy for metastatic melanoma
Slide thumbnail
RadioMedix initiates the first Ga-68 PSMA (ProstaMedix™) clinical trial for diagnosis and management of prostate cancer in U.S.
AREVA Med and RadioMedix partner to develop new treatment against Neuroendocrine Tumors
Radiomedix Partnered with Viewpoint to Win SBIR Funding
RadioMedix featured on the cover of ACS Carbohydrate Newsletter
RadioMedix signs collaborative agreement with Viewpoint Molecular Targeting, LLC of Iowa City IA

Innovating Theranostics

RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radiopharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radiolabeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology.

RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.

Recent News


RadioMedix Selected for National Cancer Institute’s Investor Initiatives and Presentation at BIO Investor Forum

October 23rd, 2017|Comments Off on RadioMedix Selected for National Cancer Institute’s Investor Initiatives and Presentation at BIO Investor Forum

Extended partnership between Radiomedix Inc and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America

October 10th, 2017|Comments Off on Extended partnership between Radiomedix Inc and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America

RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors

June 21st, 2017|Comments Off on RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors

RadioMedix, Inc., received an exclusive distributions rights for SEDECAL Preclinical PET-CT and PET-MR systems in North America.

June 19th, 2017|Comments Off on RadioMedix, Inc., received an exclusive distributions rights for SEDECAL Preclinical PET-CT and PET-MR systems in North America.

The Phase II Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance

February 6th, 2017|Comments Off on The Phase II Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance

RadioMedix and AREVA Med – SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.

October 31st, 2016|Comments Off on RadioMedix and AREVA Med – SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.